Hypoxia may be a determinative factor in COVID-19 progression
Abstract:: The disease which develops following SARS-CoV-2 virus infection, known as COVID-19, in most affected countries displays mortality from 1.5% to 9.8%. When leukocytosis due to granulocytosis, thrombocytopenia, and increased level of D-dimers are detected early during the disease course, the...
Main Authors: | Pawel Grieb, Maciej Swiatkiewicz, Katarzyna Prus, Konrad Rejdak |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Current Research in Pharmacology and Drug Discovery |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590257121000171 |
Similar Items
-
Temporal dynamics of the host molecular responses underlying severe COVID-19 progression and disease resolution
by: Eugenia Z Ong, et al.
Published: (2021-03-01) -
Predictors and clinical outcomes of silent hypoxia in COVID-19 patients, a single-center retrospective cohort study
by: Faisal Alhusain, et al.
Published: (2021-11-01) -
Prevalence of SARS-CoV-2 among community members presenting for testing in Peoria, Illinois from 21 April to 15 May 2020
by: Tulika Chatterjee, et al.
Published: (2021-01-01) -
A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients
by: Riccardo Giossi, et al.
Published: (2021-09-01) -
Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
by: Rohit Shetty, et al.
Published: (2020-01-01)